Clinical Trial Update: Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating eltrombopag in healthy subjects and volunteers with mild to severe hepatic impairment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura

Drugs mentioned

• Promacta (eltrombopag)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Purpura, Thrombocytopaenic, Idiopathic | Phase 1 | Status: COMPLETED